(PR-inside.com) Promedior, Inc. (Promedior) is a biotechnology company. The company develops therapeutic products for the treatment of fibrotic disorders and diseases. Its products under clinical development include PRM-151, and PRM-167. Promedior's products are used in the treatment of idiopathic pulmonary fibrosis, myelofibrosis, systemic fibrotic diseases, age-related macular degeneration, and retinal fibrovascular diseases. The company's PRM-151 is a recombinant form of human pentraxin-2 protein (rhPTX-2) that is formulated for intravenous injection. Its PRM-167 drug is developed for intravitreal delivery in retinal fibrovascular diseases. The company also develops formulation of Pentraxin-2 therapeutics for inhaled local delivery in lung diseases. Promedior is headquartered in ..